anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The study was planned as a randomized, parallel two-group, controlled experimental design. This research will be conducted between June 2021 and June 2022 with premature baby mothers. The sample of the study will be mothers (n = 62) of premature babies discharged from Antalya Training and Research Hospital Neonatal Intensive Care Unit. The discharge routine procedures of all mothers participating in the study will be completed and a breastfeeding guide prepared for premature babies will be sent to the phone. On the 3rd day after discharge, a reminder message will be sent to support the mother in the intervention group (n = 31) and to encourage breast milk. Throughout the program, 21 messages will be sent to the mothers in the first month after discharge, via the messaging application (whatsapp, bip, telegram, etc.) In addition, seven phone calls will be made once a week in the first month after discharge, and once a month in the eighth, twelfth and sixteenth weeks. Data will be collected by Mother-Baby Introductory Information Form, Breastfeeding Self-Efficacy Scale (short form) (BSES), Infant Feeding Attitude Scale (IIFAS) and Breastfeeding Time Assessment Form. The pre-test will be taken with the Mother-Baby Descriptive Information Form, BSES and IIFAS during the discharge routine procedures, and the post-test will be taken with the BSES, IIFAS and Breastfeeding Time Assessment Form when the baby is six months old. Ethics Committee and Institutional Permission was obtained for the study. In addition, written consent will be obtained from the participants. Statistical analysis will be done using SPSS 23.0 and significance will be evaluated at p \<0.05. Support will be received in the analysis phase of the Statistical Information Unit of Akdeniz University. It is anticipated that new information from research data will improve breastfeeding results of premature babies and guide new research.
PURPOSE:To obtain an antibody having immunological activity against Clostridium perfringens (a harmful intestinal bacteria) and useful as an active component of a food for controlling intestinal function by immunizing a chicken egg with a cell cortex antigen of Clostridium perfringens having a serum type of A and using an immunoglobulin prepared from the immunized egg as the antibody. CONSTITUTION:Clostridium perfringens having a serum type of A (e.g. NCTC 10578 strain) is cultured and a cell cortex antigen is collected from the bacterial cell. A chicken is immunized with the cell cortex antigen and eggs laid by the immunized chicken are collected and subjected to centrifugal separation, extraction with dextran sulfate, separation with various chromatographic means, etc., to separate an immunoglobulin from the egg in purified state. The obtained immunoglobulin acts as an antibody having immunological activity against Clostridium perfringens which is a harmful intestinal bacteria. Accordingly, a food having excellent effect to control intestinal function can be prepared by using the antibody as an active component.
Provided herein are compositions comprising a microbubble contrast agent, wherein at least 20% by volume of the microbubbles in the contrast agent has a size of less than 1 micron, wherein the contrast agent produces non-linear scattering when contacted by ultrasound at a frequency above 20 MHz. Provided herein are compositions comprising a microbubble contrast agent, wherein at least 10% by volume of the microbubbles in the contrast agent has a size of less than 500 nanometers, wherein the contrast agent produces non-linear scattering when contacted by ultrasound at a frequency above 20 MHz. Provided herein are compositions comprising a microbubble contrast agent, wherein at least 5% by volume of the microbubbles in the contrast agent has a size of less than 200 nanometers, wherein the contrast agent produces non-linear scattering when contacted by ultrasound at a frequency above 20 MHz. The disclosed contrast agents can be targeted contrast agents. Further provided are methods of using the compositions disclosed herein. Specifically provided are methods for producing an ultrasound image comprising: administering contrast agent to a laboratory animal; generating ultrasound at a frequency of at least 20 MHz; transmitting ultrasound at a frequency of at least 20 MHz into the subject; receiving non-linear ultrasound from the contrast agent in the subject; processing the received ultrasound to provide an image.
Patients receive idarubicin IV over 15 minutes on days 1-3, cladribine IV over 2 hours on days 1-5, and filgrastim (G-CSF) subcutaneously beginning on day 6 and continuing until blood counts have recovered for 2 days. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response after completion of course 1 may proceed to other chemotherapy or bone marrow transplantation at the discretion of the protocol investigator. Patients with extramedullary disease may receive intrathecal chemotherapy or radiotherapy to symptomatic sites.
2008960005WO Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. 5 The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen. FIG. lA FIG. lB
Subjects receiving antimicrotubule chemotherapy-based treatment will have NaF PET/CT scans at baseline and again after 8 weeks of starting treatment. A subset of subjects will have a second NaF PET/CT scan at baseline 1-8 days after the first baseline scan.
BACKGROUND: During adolescence, adolescents and young adults (AYAs) are expected to transfer their care from the pediatric environment towards an adult-focused setting. To prevent an abrupt transfer of care, it is recommended to provide AYAs with chronic conditions an adequate transition program. The aim of this paper is to describe the study protocol for the development of a transition program for AYAs with common chronic conditions (COCCOS study), using the Experience-Based Co-Design (EBCD) methodology.
METHODS AND ANALYSIS: A qualitative, participatory study is conducted in Flanders (Belgium). Study participants are AYAs (n≥15, 14-25 years old, diagnosed with type 1 diabetes, asthma, or obesity), their families, and healthcare providers (n≥15). The study is composed of eight EBCD stages: clinical site observations, in-depth interviews, trigger film, healthcare providers' feedback event, AYAs' feedback event, joint event, co-design workshops, and a celebration event. Photovoice will take place as a starting point of EBCD. Data will be analyzed using thematic analysis.
RESULTS: Data collection has started in January 2023 and is expected to be completed in May 2024. As of August 2023, over 15 clinical site observations have been conducted. A total of 18 AYAs, two parents, six healthcare providers have been enrolled and a total of 20 interviews have been conducted.
CONCLUSION: Advancing transitional care is essential for tackling negative health outcomes. Applying the innovative participatory EBCD methodology will reveal key elements of transitional care for AYAs with common chronic conditions in the development of a person-centered transition program.
PRACTICE IMPLICATIONS: Study findings will apply key elements of transitional care of AYAs with chronic conditions in the development of an adequate transition program.
Respective target positions, into which elements of a radiation therapy machine are to be moved (e.g., prior to beginning treatment of a patient), are determined. A candidate path, which describes movements of the elements from respective initial positions to the respective target positions, is defined and accessed. The candidate path is evaluated to determine whether it would result in a collision between any of the elements. The candidate path is included in a set of candidate paths when the candidate path does not result in a collision between any of the elements. A value of a measure (e.g., a measure of efficiency), used for ranking each candidate path in the set of candidate paths, is determined. A path is selected from the set of candidate paths based on the ranking.
Adhesive capsulitis (AK), also known as frozen shoulder, is a disease that negatively affects a person's quality of life by causing severe pain and limitation in the movements of the shoulder joint in all directions. Although the underlying etiology is not clear, it may develop as a result of primary (idiopathic) or secondary causes such as diabetes mellitus, malignancy, thyroid dysfunction, hypoadrenalism, Parkinson's disease, stroke, cardiac and pulmonary diseases, or local shoulder problems such as trauma, tendinitis, rupture. Prolonged immobilization after injuries is another important risk factor for adhesive capsulitis. It is more common in women between the ages of 40-60. Conservative approaches including nonsteroidal anti-inflammatory drugs or oral corticosteroid usage and physiotherapy program are the first choice for the treatment. The physiotherapy program consisting range of motion (ROM), stretching and strengthening exercises are often painful and prevent the patient's full participation. For this reason, interventional procedures such as intra-articular corticosteroid injection (IAI) and suprascapular nerve block (SSNB) are preferred to be applied before the physiotherapy program.

The aim of this study is to reveal both short and long-term effects of SSNB and IAI combination on pain, shoulder ROM, disability, and quality of life in patients with adhesive capsulitis. It is hypothesized that the addition of SSNB to IAI results in greater improvements in pain, passive and active shoulder ROMs, disability, and quality of life. The primary outcome measure of the study is determined to be the Shoulder Pain and Disability Index (SPADI), while the secondary outcome measures to be the Numeric Rating Scale (NRS), active and passive ROMs, and the Short Form 36 (SF-36).
Variants (mutants) of recombinant activated protein C (APC) or recombinant protein C (prodrug, capable of being converted to APC) that have substantial reductions in anticoagulant activity but that retain normal levels of anti-apoptotic activity are provided. Two examples of such recombinant APC mutants are KKK191-193AAA-APC and RR229/230AA-APC. APC variants and prodrugs of the invention have the desirable property of being cytoprotective (anti-apoptotic effects), while having significantly reduced risk of bleeding. The invention also provides a method of using the APC variants or prodrugs of the invention to treat subjects who will benefit from APC's cytoprotective activities that are independent of APC's anticoagulant activity. These subjects include patients at risk of damage to blood vessels or tissue in various organs caused, at least in part, by apopotosis. At risk patients include, for example, those suffering (severe) sepsis, ischemia/reperfusion injury, ischemic stroke, acute myocardial infarction, acute or chronic neurodegenerative diseases, or those undergoing organ transplantation or chemotherapy, among other conditions. Methods of screening for variants of recombinant protein C or APC that are useful in accordance with the invention are also provided.
A device to detect an object in a medical image is described. An image analysis application, executed by the device, receives the medical image as an input. The medical image is next partitioned to sub-regions. Parts of the object are detected in a selection of the sub-regions using a deep-learning neural network (DNN) model. Bounding boxes for the selection are also determined. The bounding boxes are evaluated based on a confidence score detected as above a threshold level. The confidence score designates the parts as contained within the selection. Next, a region of interest (ROI) is determined as a group including the selection. Similar orientations associated with the bounding boxes are comparable to similar orientations of a positive training model of the DNN model. Furthermore, the selection is designated as the ROI within the medical image. The medical image is provided with the ROI to a user.
The invention relates to a traditional Chinese medicine preparation for treating ringworm of sheep. The preparation comprises an external Chinese herbal medicine preparation and an internal Chinese herbal medicine additive. The external Chinese herbal medicine preparation is prepared from the following raw materials in parts by weight: 30-40 parts of fresh gingers, 10-15 parts of galangal, 10-15 parts of northeastern stichopus japonicus, 10-20 parts of turmeric, 10-20 parts of notopterygium roots, 20-30 parts of raw propolis, 120-180 parts of absolute ethyl alcohol, 60-90 parts of distilled water and 65-90 parts of glycerinum. The internal Chinese herbal medicine additive is prepared from the following raw materials in parts by weight: 15-25 parts of capillary artemisia, 10-20 parts of radix angelicae pubescentis, 10-15 parts of coptis chinensis, 10-15 parts of golden cypress, 10-15 parts of rheum officinale, 15-30 parts of houttuynia cordata, 15-25 parts of radix lsatidis and 10-30 parts of liquorice. Tinea is treated everyday by the traditional Chinese medicine preparation provided by the invention for continuous 20 days or the internal Chinese herbal medicine additive provided by the invention is added into a mixed beneficiated burden material according to dosage of 30-40g per day for each sheep for continuous 5 days so as to have a better curing effect. The external Chinese herbal medicine preparation and the internal Chinese herbal medicine additive are combined in use to have a better curing effect. The preparation provided by the invention is non-toxic, harmless and free from residue.
The duration of the program is 24-weeks, 2-times a week, for up to 50 minutes per session. The sessions will be divided into three phases: the initial phase (10 minutes) will consist of a 5-minute walk followed by a joint warm-up; fundamental phase (25 minutes) will work in an exercise circuit, this circuit will consist of 4 cycles, with 8 exercises each, with a duration of 50 seconds and a rest of 15 seconds, for the exchange of exercise; and return to calm (10 minutes), where we will perform muscle stretching.
Obesity remains a significant concern for dogs and cats, and reducing or eliminating treats is commonly recommended as a strategy for weight management. Caregivers can struggle with adherence to such dietary recommendations. Previous research suggests caregivers are reluctant to reduce treats but there is limited understanding of the underlying factors contributing to these behaviours and decisions. The objective of this study was to explore caregivers' motivations and barriers to reducing treat feeding, and their reported capability to do so. An online questionnaire including multiple choice and Likert scale questions was disseminated to dog and cat caregivers (n=1053) primarily from Canada and the USA from September to November 2021. Caregivers commonly expressed a wide range of motivations to reduce treat feeding with their pet, though barriers to reducing treat feeding were less defined. Changing their pet's routine was a reported barrier by more than 30% of respondents and was predictive of caregivers finding reducing treat giving to be difficult (OR=1.67, p=0.017). Results from multivariable logistic regression also revealed that caregivers who consider their companion animal to be obese as more likely to perceive reducing treats to be difficult. The results highlight the role of treats in the relationship and routine of caregivers' and their pets, and the importance of considering the individualised needs and circumstance of the caregiver and pet in veterinary discussions surrounding reducing treat feeding. Identifying these perspectives can improve self-efficacy with veterinary nutrition recommendations surrounding treats.
Patients will have lesional dosimetry with 124I PET/CT performed to quantify the baseline iodine avidity of index metastatic lesion(s). Patients will then receive vemurafenib (960 mg orally BID) for about 4 weeks, after which a second 124I PET/CT will be performed. For patients in whom the second 124I PET/CT demonstrates that \> or = 2000 cGy can be achieved in at least one tumor with \< 300 mCi of 131I, Thyrogen-stimulated standard dosimetry \& therapeutic 131I will be performed/administered concurrently with vemurafenib. The drug will then be discontinued \& tumor assessments will be conducted with serial radiologic scan(s) \& thyroglobulins (scans will be performed at baseline, before 131I, 3-4 months following 131I, \& 6 months after 131I). Patients whose tumors fail to demonstrate adequate iodine incorporation following vemurafenib to warrant 131I therapy, the study drug will be discontinued, a final tumor assessment will be performed, \& the patient will be taken off the study.
This is an exploratory, single group, observational study involving patients recruited from the dialysis patient population of the London Health Science Centre (LHSC) Regional Renal Program. Recruited patients will undergo insertion of the Reveal LINQ insertable cardiac monitoring system and will continuously be examined over a time period of up to 12 to 24 months to gather data on the incidence of arrhythmia.

Those patients enrolled into the study will have their first study session on their midweek dialysis treatment day (Wednesday or Thursday) at St. Joseph's Hospital. During the first study visit, all participants will have an external multichannel ECG, CT scan, CT angiogram, and 2D echo done. In addition to this, all participants will have non-invasive monitoring of circulatory stress using the CVInsight contact device, and blood work will be drawn. Within one month, all participants will have a second study visit where they will undergo the same study procedures as in session one with the addition of up to 30 minutes of intradialytic exercise. This visit will also take place at St. Joseph's Hospital on a mid-week dialysis treatment day. If a patient would like to, they will then undergo an insertion procedure of the Reveal LINQ insertable cardiac monitoring system on a dialysis or non-dialysis treatment day at University Hospital. Dr. Allan Skanes (CoInvestigator) will perform this procedure at his earliest convenience. The implantable loop recorder will be interrogated at least once a month for up to 12 months to retrieve the information that has been recorded during their hemodialysis treatment. During this time, the patient participant will complete a questionnaire too using the LEVIL application. Then, 12 months after the initial insertion of the device, a follow-up call will be completed by a member of the research team where the patient will have the choice to have the device removed if desired. If the patient chooses to keep the device, we will monitor the implantable loop recorder for another year and the patient will be transferred to LHSC's Inherited Heart Rhythm Clinic at University Hospital for clinical monitoring after this. Completion of the questionnaire will continue during this time. If they choose to have the device removed, the cardiac electrophysiologist will remove the device at his earliest convenience.

Bloodwork will be obtained pre and post dialysis as well as at peak stress of each imaging session. This will allow us to assess for relevant biomarkers of oxidative stress, myocardial ischemia, and volume overload.
For patients suffering from hepatocellular carcinoma, a palliative treatment can be proposed if tumor expansion is limited to the liver. One of palliative treatment is the the Selective Internal Radiation Therapy (SIRT) with Therasphere®. This treatment is made secure by performing a diagnostic angiogram coupled with a hepatic perfusion scintigraph with which patients at risk of complications are identified and excluded. The treatment objective, with the standard dosimetric approach, is to deliver an absorbed dose of 120 ± 20 Gy to the treated hepatic volume, most often one lobe. Recent retrospective trials show that an optimized dosimetric approach, considering the dose absorbed by the tumor, is technically achievable and would probably make it possible to obtain a better effectiveness. In our experience, treatment personalisation have been described to be used for 60% of the patients with a tumor larger than 7 cm underlying the clinical impact of this new approach.
During the 30-month Main Trial (RCT) Period, patients will be randomized to usual care (Arm 2, n=425). Data collection for post-discharge AE determination will occur during both periods.
Skeletal muscle mito ATP production in young people are stimulated by insulin when infused with a mixture of amino acids while clamping blood glucose at the basal level. Our preliminary results indicate that this effect on mito ATP production is directly related to amino acid levels. Recent publications indicated that infusion of insulin with amino acids specifically stimulate muscle mitochondrial protein synthesis with no effect on synthesis or contractile proteins or sarcoplasmic proteins. The recent publications also indicated that intracellular amino acid anabolic sensors are stimulated by amino acids. It appears that BCAA, especially leucine has a specific effect in stimulating intracellular signaling or translation of mRNA to protein synthesis. It has been shown that amino acids, especially leucine, stimulate protein synthesis by activation of the mTOR pathway in mTOR phosphorylates p70S6 kinase which in turn phosphorylates the ribosomal S6 protein, resulting in increased activity of the protein synthesis complex. Activated mTOR also phosphorylates eIF4E-BP1 and activates the protein synthesis initiation complex. It is the abundance of specific mRNAase that determines synthesis of which specific proteins are promoted. Our preliminary data supports that amino acids selectively promotes muscle mitochondrial protein synthesis by enhancing the abundance of transcripts of genes that encode mitochondrial proteins. Administration of an amino acid mixture, specifically BCAA, is proposed as a stimulant of muscle mitochondrial ATP production. Secondary measurements will be performed to understand the underlying mechanism of enhanced muscle ATP production. These results are likely to contribute to our understanding of the basic mechanisms of the regulation of mitochondrial biogenesis in humans which will have potential future application.

This is a cross-sectional study between young and old. The study will use the new proteomic techniques established in our laboratory to profile and quantify mitochondrial protein synthesis in the participants. The combination of metabolic labeling with stable isotope and measuring synthesis rates of specific mito proteins by tandem mass spectrometry will determine whether actual stimulation by BCAA occurs differentially in young and elderly.
NEW MATERIAL:The radioactive compound of formula I [Br* is radioactive Br; R is group of formula II (R1 is H or lower alkyl), formula III (R2 is R1, halogen, lower haloalkyl or lower alkoxy) or formula IV (R3=R1; dotted line represents single or double bond)]. EXAMPLE:[<82>Br]-2-bromospiroperidol. USE:A drug. It has high affinity with dopamine receptor and is useful as a nuclear medical diagnostic agent for dopamine receptor or as a radioactive medicine. It is expected to be useful in the field of cancer such as mammary cancer in view of the relationship between cancer and a dopamine receptor. PREPARATION:The compound of formula I can be produced e.g. by diazotizing a 2-aminobutyrophenone derivative of formula V and reacting the resultant diazonium salt of formula VI [Y is halogen ion, HSO4<-> or anion of formula VII or VIII (A is SO3 or CO2) with a radioactive HBr or metal bromide optionally in the presence of copper powder, etc.